CAJ | 학술논문

CD137(4-1BB,ILA,TNFRSF9)分子是介导T细胞活化的协同刺激信号,经由CD137/CD137L信号通路增强免疫反应成为肿瘤免疫治疗的潜在靶点.CD137主要表达在活化的T细胞、自然杀伤细胞和树突状细胞(DC)等肿瘤免疫相关细胞,研究发现CD137配体或活化型CD137单抗介导的共刺激信号可促进T细胞等免疫细胞的增殖、诱导细胞因子的分泌以及减少活化诱导的细胞死亡(AICD),维持CD8+T细胞存活状态、增强NK活性.大量动物抗肿瘤尤其是低免疫源性肿瘤临床前实验,单独或者联合其它免疫调节分子作用于4-1BB/4-1BBL途径,已取得良好效果,为临床治疗研究奠定了基础.
CD137(4-1BB,ILA,TNFRSF9)분자시개도T세포활화적협동자격신호,경유CD137/CD137L신호통로증강면역반응성위종류면역치료적잠재파점.CD137주요표체재활화적T세포、자연살상세포화수돌상세포(DC)등종류면역상관세포,연구발현CD137배체혹활화형CD137단항개도적공자격신호가촉진T세포등면역세포적증식、유도세포인자적분비이급감소활화유도적세포사망(AICD),유지CD8+T세포존활상태、증강NK활성.대량동물항종류우기시저면역원성종류림상전실험,단독혹자연합기타면역조절분자작용우4-1BB/4-1BBL도경,이취득량호효과,위림상치료연구전정료기출.
CD137 (4-1 BB),a member of the TNF receptor superfamily,is an activation-induced T-cell co-stimulatory molecule.Upon ligand binding,CD137 up-regulates survival genes,enhances cell division,induces cytokine production,and prevents activation-induced cell death in T cells.Growing evidence indicates that agonist anti-4-1BB monoclonal antibodies possess strong antitumor properties,and combination therapy of anti-4-1 BB with other anticancer agents has robust tumor-regressing abilities against non-immunogenic or poorly immunogenic tumors.In addition,targeting of tumors with variants of 4-1BBL directed against 4-1BB also have potent antitumor effects.In this review,we discuss the basis of the therapeutic potential of targeting the 4-1BB-4-1 BBL pathway in cancer treatment.